| 主权项 |
1. A pharmaceutical preparation for treating death-receptor ligand resistant Hodgkin lymphoma or human T-cell leukemia virus type 1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL), comprising a therapeutically effective amount of:
a) at least one rocaglamide derivative of the formula (I) and/or a pharmaceutically acceptable salt thereof; and b) TRAIL, wherein the compound of formula (I) has the following structure: wherein: R1 is selected from hydrogen, halogen and alkyl; R2 is selected from halogen, alkyl and alkoxy; R3 is selected from hydrogen, halogen and alkyl; R4 is selected from halogen, alkyl and alkoxy; or R2 and R3 together form a —OCH2CH2O— unit; R5 is selected from hydroxyl, acyloxy, amino, monoalkylamino, dialkylamino and —NR12—CHR13—COOR14, with R12 being selected from hydrogen and alkyl, R13 being selected from phenyl and benzyl, which both may carry a substituent from the group hydroxyl, indolyl and imidazolylmethyl, and alkyl which may be substituted by a group selected from OH, SH, alkoxy, thioalkoxy, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl, carboxamide and hydroxyl groups; or R12 and R13 together form a —(CH2)3— or —(CH2)4— group; R14 being selected from alkyl and benzyl; in which case R6 is hydrogen, or R5 and R6 together form an oxo or hydroxyimino group; R7 is hydrogen; R8 is selected from hydrogen, —COOR15 and CONR16R17, wherein R15 and R16 are independently selected from hydrogen and methyl, and R17 is selected from hydrogen, methyl, 4-hydroxybutyl and 2-tetrahydrofuryl; R9 is selected from phenyl which is optionally substituted, and hetaryl which is optionally substituted; R10 is selected from hydrogen, halogen, alkyl and alkoxy, and R11 is selected from hydrogen, hydroxyl, halogen, alkoxy and alkyl; or R10 and R11 are in ortho-position to each other and together form a —OCH2O— unit; or a pharmaceutically acceptable salt thereof. |
